Brad H. Vale, PhD, DVM

Brad H. Vale, PhD, DVM
Founder and General Partner

Brad is a Founding General Partner of Treo Ventures.

Brad was Head of Johnson & Johnson Development Corporation (JJDC) from 2011 to 2015. JJDC is Johnson & Johnson’s venture investing arm and has offices in Silicon Valley, Boston, Shanghai, London and Tel Aviv. He established JJDC’s west coast office in 1997 and was an investor in medical devices, healthtech, and biotech for J&J from 1992-2011. JJDC invests to support operating company interest in new technologies and also does venture investing to explore new technologies and business models. Brad successfully led the strategy for building a neuromodulation portfolio in the 2001-2015 era and served on a number those company boards.

Prior to JJDC, Brad worked in preclinical surgery and product development at Ethicon, J&J’s wound closure company, in projects to develop lasers, blood compatible polymers, wound healing stimulation, internal and external stapling and suture materials. Before joining JJDC he was part of J&J’s Corporate Office of Science and Technology focused on surgical innovation and biomaterials for medical device applications.

Brad currently serves on the boards of Hyalex Orthopaedics, Inc., Intuity Medical, Inc. and ShiraTronics, Inc. Brad previously served on the board of Nevro (NYSE: NVRO) where he was an investor prior to the IPO. Additionally, Brad served on the boards of several private companies that were ultimately acquired by J&J.

Dr. Vale received a PhD in Biomedical Engineering from Iowa State University on the development of blood compatible polymers and a Doctor of Veterinary Medicine from Washington State University.





Copyright 2024 Treo Ventures. All rights reserved.